{"id":"14f5acb7-db24-5667-a197-6b85a36b9cf3","stable_key":"8182578e-8d21-598e-a3cb-e62d480d2251:myricetin-total-exposure","predicate":"yields_measured_exposure","statement":"Following 50 or 100 mg/kg oral myricetin in rats, reported absolute bioavailability was 9.62% or 9.74%; plasma samples underwent beta-glucuronidase/sulfatase hydrolysis before quantification.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"10703811-520f-53a8-bc27-1e004f79fd3e","mechanism_event_label":"The measurement includes releasable conjugates, not just free parent.","subject":{"id":"fafe05e7-4874-56e6-a42a-2ebf1ab2dd57","slug":"myricetin","display_name":"Myricetin","entity_type_key":"small_molecule"},"object":{"id":"d739e498-7864-5903-b373-15db5cfa1f0c","slug":"rat-total-myricetin-exposure","display_name":"Rat plasma total hydrolysable myricetin exposure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"10703811-520f-53a8-bc27-1e004f79fd3e","stable_key":"8182578e-8d21-598e-a3cb-e62d480d2251:myricetin-total-exposure-event","event_type":"observed_relationship","label":"The measurement includes releasable conjugates, not just free parent.","description":"Following 50 or 100 mg/kg oral myricetin in rats, reported absolute bioavailability was 9.62% or 9.74%; plasma samples underwent beta-glucuronidase/sulfatase hydrolysis before quantification.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"fafe05e7-4874-56e6-a42a-2ebf1ab2dd57","slug":"myricetin","display_name":"Myricetin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"d739e498-7864-5903-b373-15db5cfa1f0c","slug":"rat-total-myricetin-exposure","display_name":"Rat plasma total hydrolysable myricetin exposure","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Rat oral/intravenous UPLC-MS/MS comparison.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Do not use these percentages as human absorption or unconjugated target exposure.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Myricetin collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"myricetin","display_name":"Myricetin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The measurement includes releasable conjugates, not just free parent.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Quantitative determination of myricetin in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and its absolute bioavailability. · 2014 · https://pubmed.ncbi.nlm.nih.gov/24357136/ · DOI 10.1055/s-0033-1363220","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"ee90b4e5-4f81-5a96-995c-c7793b96f474","evidence_kind":"source_excerpt","locator":"Lines 12-18","start_line":12,"end_line":18,"excerpt":"## myricetin-total-exposure\nThe measurement includes releasable conjugates, not just free parent.\nFollowing 50 or 100 mg/kg oral myricetin in rats, reported absolute bioavailability was 9.62% or 9.74%; plasma samples underwent beta-glucuronidase/sulfatase hydrolysis before quantification.\nModel: Rat oral/intravenous UPLC-MS/MS comparison.\nLimitations: Do not use these percentages as human absorption or unconjugated target exposure.\nEvidence access: Primary abstract\nQuantitative determination of myricetin in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and its absolute bioavailability. · 2014 · https://pubmed.ncbi.nlm.nih.gov/24357136/ · DOI 10.1055/s-0033-1363220","model_system":"Rat oral/intravenous UPLC-MS/MS comparison.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"58045cd9-3b27-5469-bb4b-e1c6a9bdca34","stable_key":"import-8182578e-8d21-598e-a3cb-e62d480d2251","title":"Myricetin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"0abf512275cf3aae9e4ec8544f1cde97e0155d0cfb5be12a193cdd5a898386a7","revision_id":"422e342f-a55c-5e73-ba98-43df560f49b9","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}